C-terminal AAT Peptides as Pre-Transplant Biomarkers for CLAD Risk Stratification

<title>Extract</title> Lung transplantation (LuTx) remains the final treatment option for patients with end-stage pulmonary disease. Despite improvements in surgical techniques, immunosuppressive regimens, and post-transplant care, survival after LuTx remains lower than for other solid organ transplants [1–3]. A major barrier to long-term success is chronic lung allograft dysfunction (CLAD), which affects nearly 50% of recipients within five years. CLAD presents in subtypes including bronchiolitis obliterans syndrome (BOS), restrictive allograft syndrome (RAS), mixed phenotypes, or undefined forms [4]. LuTx recipients are particularly vulnerable to respiratory infections due to environmental exposure and chronic immunosuppression. These infections, alongside alloimmune responses, are key drivers of allograft injury and CLAD progression [5–7]. Therefore, early biomarkers that can predict CLAD risk are needed.

Authors

Institutions

Publication Details

Journal
ERJ Open Research
Published
2025-11-20
DOI
https://doi.org/10.1183/23120541.01078-2025
Primary Topic
Transplantation: Methods and Outcomes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

C-terminal AAT Peptides as Pre-Transplant Biomarkers for CLAD Risk Stratification

Sabina Janciauskiene, Patrick Zardo, Benjamin Coiffard, Benjamin Renaud‐Picard et al.
ERJ Open Research
Transplantation: Methods and Outcomes
article

C-terminal AAT Peptides as Pre-Transplant Biomarkers for CLAD Risk Stratification

Sabina Janciauskiene, Patrick Zardo, Benjamin Coiffard, Benjamin Renaud‐Picard, Tomoyuki Nakagiri, Arjang Ruhparwar, F. Ius, Sabine Wrenger, Adrien Tissot, Stephan Immenschuh, A. Magnan, Jan Fuge, Michael Kiehntopf, Julia Held, Antoine Roux, Friedemann Börner
article en

Abstract

<title>Extract</title> Lung transplantation (LuTx) remains the final treatment option for patients with end-stage pulmonary disease. Despite improvements in surgical techniques, immunosuppressive regimens, and post-transplant care, survival after LuTx remains lower than for other solid organ transplants [1–3]. A major barrier to long-term success is chronic lung allograft dysfunction (CLAD), which affects nearly 50% of recipients within five years. CLAD presents in subtypes including bronchiolitis obliterans syndrome (BOS), restrictive allograft syndrome (RAS), mixed phenotypes, or undefined forms [4]. LuTx recipients are particularly vulnerable to respiratory infections due to environmental exposure and chronic immunosuppression. These infections, alongside alloimmune responses, are key drivers of allograft injury and CLAD progression [5–7]. Therefore, early biomarkers that can predict CLAD risk are needed.

ERJ Open Research
Université de Versailles Saint-Quentin-en-Yvelines (FR), Université Paris Cité (FR), Centre Hospitalier Universitaire de Nantes (FR), Medizinische Hochschule Hannover (DE), Sorbonne Paris Cité (FR), German Center for Lung Research (DE), Jena University Hospital (DE), Hôpital Bichat-Claude-Bernard (FR), Hôpital Civil, Strasbourg (FR), Université de Strasbourg (FR), Friedrich Schiller University Jena (DE)
Openalex Percentile: Top 46%
Transplantation: Methods and Outcomes
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.